Therefore, our data strongly support the potentiality of VEGF as a therapeutic tool for the treatment of motoneuronal diseases, reinforcing previous findings showing that this factor can prevent motoneuronal death in animal models of ALS (Azzouz et al., 2004; Storkebaum et al., 2005; Wang et al., 2007; Sathasivam, 2008). Here, VEGFA is linked to amyotrophic lateral sclerosis.